Phibro Animal Health reports 10% Q3 sales growth, raises FY2026 guidance midpoint

Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read

Key Changes

• high

  Q3 net sales rose 10% to $383.5M, driven by 13% growth in Animal Health segment; adjusted EBITDA up 11% to $60.8M and adjusted diluted EPS increased 19% to $0.76.

  Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
• high

  Company raised FY2026 guidance ranges, now expecting net sales of $1.46B–$1.50B (14% growth at midpoint) and adjusted EBITDA of $247M–$255M (37% growth at midpoint).

  Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
• medium

  Expanded revolving credit facility by $125M to $435M total capacity on April 28, providing enhanced operating flexibility and strengthened liquidity.

  Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →